Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PharmaBiome bacterial consortium (Cancer IO)
- Development stage
- Preclinical
- Lead developer
- PharmaBiome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal, Endoscopic, Enteroscopic, Colonoscopy, Nasoduodenal
01
Overview
PharmaBiome's Cancer IO program is a preclinical-stage microbiome therapy consisting of a rationally assembled bacterial consortium. Developed by the Swiss biotechnology company PharmaBiome, the therapy is designed to modulate the gut microbiome to enhance the host's anti-tumor immune response. The consortium is produced using a proprietary co-culture technology in bioreactors, ensuring a stable and functional mixture of bacterial strains. It is intended to be used as an adjunct to existing cancer immunotherapies, such as immune checkpoint inhibitors, to improve patient response rates by addressing microbiome-mediated resistance or lack of efficacy.
- Other names
- Bacterial Consortium (Cancer IO)PharmaBiome Cancer IO consortiumPharmaBiome microbiome therapy (Cancer)
Beyond the preview
Go deeper on PharmaBiome bacterial consortium (Cancer IO).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharmaBiome bacterial consortium (Cancer IO).